Hulamin - Continued Recovery Name? Disc to BV, Well off ATH's
Hulamin (231c) - if not already held, it might be worth a further look. Small position due to liquidity/size.
Share price -93% off all-time highs.
Trading at discount to book value.
Turnaround efforts started in 2019 largely concluded.
Order books healthy.
Mkt Cap R758m vs Revenue of R8.6bn (down 20% in 2020).
Cost reductions implemented however cost reductions obscured by firmer ZAR.
Shares outstanding lower vs 5 years ago (~328m vs ~300m)
Revenue earned from SA roughly the same as that from Europe - ZAR hedge characteristics.
Con: For FY 2020, no dividend declared due to uncertain outlook.
Technical Structure: Emerging from bullish flag, rebounding off back-test of 200-day for commencement of upward trend.
Stop-loss: 189c
Share price -93% off all-time highs.
Trading at discount to book value.
Turnaround efforts started in 2019 largely concluded.
Order books healthy.
Mkt Cap R758m vs Revenue of R8.6bn (down 20% in 2020).
Cost reductions implemented however cost reductions obscured by firmer ZAR.
Shares outstanding lower vs 5 years ago (~328m vs ~300m)
Revenue earned from SA roughly the same as that from Europe - ZAR hedge characteristics.
Con: For FY 2020, no dividend declared due to uncertain outlook.
Technical Structure: Emerging from bullish flag, rebounding off back-test of 200-day for commencement of upward trend.
Stop-loss: 189c
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.